



The European Society for Medical Oncology (ESMO) is Europe's leading professional society providing training for medical oncologists as well as clinical guidelines and multidisciplinary programs for oncology healthcare professionals, working to ensure optimal care for cancer patients. ESMO is dedicated to providing medical oncologists around the world with the information, knowledge, and experience that are the backbones of excellence in multidisciplinary clinical practice.

The objective of the European Society for Medical Oncology (ESMO) is to nurture new scientific advances in oncology and to support and educate oncologists and patients at all levels, in order **to improve the quality of cancer treatment and care.**

ESMO strives to certify and maintain the highest standards of overall care for cancer patients by:

- **gathering** and **disseminating** oncology research results
- **supporting** oncologists and cancer patients with guidelines, policies and publications
- **offering** state-of-the-art scientific, educational and professional training programs in oncology
- **accrediting** professionals institutions and institutional programs
- **raising awareness** to influence political and healthcare issues related to oncology

With a worldwide membership base, ESMO is represented in every European country and the major geographical areas of the world. Since its inception in 1975, ESMO has consistently promoted its belief that every cancer patient is entitled to the best possible treatment available. Through the years, the Society has strived to meet the needs of both oncologists and patients. For oncology professionals, **ESMO serves and offers support to its members** in their daily practice and careers by sharing knowledge and expertise through scientific and educational activities. For patients, **ESMO partners with cancer patient associations and groups**, by promoting direct and pro-active involvement of patients in educational, political, and networking activities. For the benefit of both, professionals and patients, in 2006 ESMO became active at the political level in order to influence issues which could impact the oncology community.

The use of medicine is a fundamental aspect of cancer therapy and, consequently, cancer patients need to be treated by qualified medical oncologists. ESMO supports multidisciplinary oncology and through its flagship scientific journal, *Annals of Oncology*, publishes research results on all aspects of clinical oncology.

Donations to the ESMO Foundation help support ESMO activities as well as cancer research.

More information on the Society and its activities can be found at www.esmo.org.



**Håkan Mellstedt, Prof. MD, PhD, Sweden
ESMO President**

Education

Degrees: MD Karolinska Institute 1969
Ph.D. Karolinska Institute 1974

Residency: Serafimer Hospital 1969-1973 Internal Medicine
Serafimer Hospital 1973-1975 Hematology
Karolinska Hospital 1980-1983 Oncology

Specialization: Internal Medicine, Oncology and Hematology

Board Certified: Internal Medicine, Oncology and Hematology

Professional Experience

Managing Director, CancerCentreKarolinska (CCK), Karolinska University Hospital, Stockholm, Sweden
Chief Physician, Departments of Oncology and Hematology, Karolinska University Hospital

Special Recognition

Main areas of research interest: Tumor immunology and immunotherapy, focus on the development of antibody treatment and cancer vaccines in gastrointestinal and chronic B-cell malignancies

Principal investigator: Interferon treatment of myeloma, Monoclonal antibody treatment of CLL and colorectal carcinoma. Vaccine development in myeloma, CLL, colorectal carcinoma and pancreatic carcinoma

Awards: Alfaferone Prize (Italy 1989), J. Waldenström Award (USA 2001)

Editorial Board: Cancer Immunology Immunotherapy

Faculty member: Professor of Oncologic Biotherapy, Karolinska Institute; ESMO Hematologic malignancies and Clinical Discussion Forum

Committee member: ESMO President (2006-2007), ESMO Board of Directors and Executive Committee (since 2002), Chair ESMO National Representatives Committee (2002-2005), Chair ESMO Developing Countries Task Force (2003-2006), Chair ESMO Translational Research Task Force (2005), ESMO Guidelines Task Force (1999-2004)

Society member: ESMO, ASCO, Swedish Society of Oncology (Chair 1993-2000), Cancer Society in Stockholm

Languages: Swedish, English

Other: Board of Trustees, ESMO Foundation, Swedish Childhood Foundation, International Myeloma Foundation, Myeloma Research Foundation, King Gustav V Jubilee Fund



**José Baselga, MD, Spain
ESMO President-Elect**

Education

- Degrees:** MD Universidad Autonoma of Barcelona (1982)
Residency: Internal Medicine at Vall d'Hebron University Hospital, Barcelona, Spain and State University of New York
Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center, New York, USA
Specialization: Internal Medicine Medical Oncology, Hematology

Professional Experience

Chairman, Medical Oncology Service and Director of the Division of Medical Oncology, Hematology, and Radiation Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
Professor of Medicine, Universidad Autonoma de Barcelona, Spain
Staff, Breast Medicine Service, Memorial Sloan-Kettering Cancer Center (1992-1996)

Special Recognition

Main areas of research interest: Clinical breast cancer, translational research in growth factor receptors

Awards: Premio Iniciativa BMW (*BMW Initiative Award*). Barcelona, Spain; Jean H. Lubrano Distinguished Visiting Scholar Lecture. Dana-Farber and Harvard Medical School, Boston, USA (2007); City Award "La Clau de la Ciutat de Barcelona" ('*The Key of the City of Barcelona*'). Barcelona, Spain (2006); ESMO Award (2005), Premio a los Valores Cívicos (*Civic Value Award*). Sociedad Círculo Ecuestre, Barcelona, Spain (2005); ESTRO Honorary membership Award (2003), Unrestricted Bristol Myers Squibb Cancer Grant Award (2002-2006), ASCO Career Development Award (1995)

Editorial Board: Annals of Oncology, Cancer Cell, Clinical Cancer Research, Journal of Clinical Oncology and Investigational New Drugs

Faculty member: ESMO Basic cancer research

Committee member: ESMO Scientific Committee Chair 29th ESMO Congress, Scientific Chair ECCO 13, Vice-Chair ESMO Young Oncologist Working Group, ESMO International Symposium (EIS) Working Group

Society member: ESMO, ASCO, AACR, EORTC

Languages: Spanish, English, Catalan

Other: Involved in the clinical development of several new agents including: trastuzumab, erbitux, gefitinib, erlotinib, EMD 72000, ras farnesyltransferase inhibitors, m-TOR inhibitors, TGF β inhibitors, PI3K inhibitors and a variety of antiangiogenic agents



Roberto Labianca, MD, Italy
ESMO Representative in World Congress on Gastrointestinal Cancer
Scientific Committee

Degrees: Degree in Medicine and Surgery on 1975
Specialization: Specialization in Medical Oncology on June 1978
Specialisation in Allergology and Clinical Immunology on July 1981

Professional Experience

Head of Unit of Medical Oncology – Ospedali Riuniti di Bergamo
(1995 to 1997) Responsible of the Group on Gastrointestinal Cancer of Medical Oncology Department S. Carlo Borromeo Hospital (Milan)
(1988 to 1997) Deputy Director of Medical Oncology Department S. Carlo Borromeo Hospital
(1980 to 1988) Assistant of Medical Oncology Department S. Carlo Borromeo Hospital
(1975 to 1980) Research fellow of Medical Oncology Department S. Carlo Borromeo Hospital

Membership in Scientific Societies:

- AIOM (Associazione Italiana di Oncologia Medica):
 - o Regional Councillor (1986/1988)
 - o Co-ordinator in Lombardia (1989/1993)
 - o National Councillor (1993/1995)
 - o National Secretary (1995/now)
- CIOM (Collegio Italiano degli Oncologi Medici) from 1985
- SIC (Società Italiana di Cancerologia) from 1984
- ESMO (European Society for Medical Oncology):
 - o National Representative for Italy (1994/now)
- ASCO (American Society of Clinical Oncology) from 1994
- MASCC (Multinational Association for Supportive Care of Cancer) from 1994
- SICP (Società Italiana di Cure Palliative) from 1989
- EAPC (European Association of palliative Care) from 1992
- SITILO (Società Italiana per le Terapie Integrate Locoregionali in Oncologia) from 1995

Membership in Scientific Groups:

- GISCAD (Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente), Scientific Secretary from 1990
- ITMO (Italian Trials in Medical Oncology), Member of National Executive Council from 1991
- GIVIO (Gruppo Italiano per la valutazione degli interventi in Oncologia) from 1989
- EORTC (European Organization for the Research and Treatment of Cancer) as:
Active Member of Gastrointestinal Cooperative Group from 1987
- GITCLO (Gastrointestinal Tumour Cooperative Groups Liaison Office) as:
National Representative for Italy from 1995
- IWGCRG (International Working Group for Colorectal Cancer) from 1995

Editorial Board: Tumori, Quaderni Cure Palliative, Progress in Colorectal Cancer, Tekve (Update in Oncology and Hematology), Annals of Oncology, Journal of Chemotherapy